MAPKAPK2

MAP kinase-activated protein kinase 2

86,994 patent compounds predicted against MAPKAPK2, 52,997 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL261816	0.44	12/20
SCHEMBL273473	0.67	7/20
SCHEMBL78108	0.49	6/20
SCHEMBL56219	0.44	6/20
SCHEMBL272856	0.41	6/20
SCHEMBL88260	0.53	5/20
SCHEMBL376258	0.50	5/20
SCHEMBL78493	0.46	5/20
SCHEMBL64988	0.43	5/20
SCHEMBL12222	0.56	4/20
SCHEMBL231077	0.52	4/20
Hydrochloric Acid (SCHEMBL376202)	0.51	4/20
SCHEMBL330953	0.43	4/20
SCHEMBL164105	0.42	4/20
SCHEMBL376298	0.42	4/20
SCHEMBL273395	0.41	4/20
Adrenoglomerulotropin (SCHEMBL356345)	0.67	3/20
SCHEMBL218021	0.55	3/20
SCHEMBL12136	0.50	3/20
SCHEMBL272916	0.50	3/20

Germline variants in MAPKAPK2 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full MAPKAPK2 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to MAPKAPK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma	PHASE4	UNKNOWN
Molecular Mechanisms of Type 2 Diabetes Mellitus	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Clinical Evaluation of the Effect of Metformin in Sepsis	PHASE3	UNKNOWN
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma	PHASE1/PHASE2	COMPLETED
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies	PHASE1/PHASE2	RECRUITING
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.	PHASE2	UNKNOWN
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant	PHASE2	RECRUITING
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer	PHASE2	UNKNOWN
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
MEK162 for Patients With RAS/RAF/MEK Activated Tumors	PHASE2	COMPLETED
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	PHASE2	COMPLETED
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...	PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations	PHASE2	ACTIVE_NOT_RECRUITING
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS	PHASE2	COMPLETED
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma	PHASE2	UNKNOWN
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia	PHASE1	RECRUITING
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma	PHASE1	COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer	PHASE1	COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)	PHASE1	COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
p38 Mitogen-Activated Protein Kinase (MAPK) and Steroid Insensitivity in Asthma	nan	COMPLETED
Glutamate Supplementation in Young Men	nan	COMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a MAPKAPK2 binder may also engage these)

Protein	Name	Similarity
P49138	—	0.998	P49138 →
P49139	—	0.997	P49139 →
MAPKAPK3	MAP kinase-activated protein kinase 3	0.987	landscape →
Q66H84	—	0.984	Q66H84 →
Q3UMW7	—	0.982	Q3UMW7 →
Q3SYZ2	—	0.980	Q3SYZ2 →
Q7XQP4	—	0.973	Q7XQP4 →
Q9FFP9	—	0.971	Q9FFP9 →
P49136	—	0.970	P49136 →
Q6ZI44	—	0.969	Q6ZI44 →
Q75H77	—	0.969	Q75H77 →
O88506	—	0.969	O88506 →
A2YNT8	—	0.968	A2YNT8 →
Q0D4J7	—	0.968	Q0D4J7 →
A0A8I5ZNK2	—	0.967	A0A8I5ZNK2 →
A9TF79	—	0.967	A9TF79 →
Q6P9R2	—	0.967	Q6P9R2 →
Q863I2	—	0.966	Q863I2 →
P43292	—	0.966	P43292 →
Q9Z1W9	—	0.965	Q9Z1W9 →
Q9C958	—	0.965	Q9C958 →
P43291	—	0.965	P43291 →
STK39	STE20/SPS1-related proline-alanine-rich protein kinase	0.963	landscape →
Q5N942	—	0.963	Q5N942 →
Q75LR7	—	0.963	Q75LR7 →
Q940H6	—	0.962	Q940H6 →
A2ZAB5	—	0.960	A2ZAB5 →
P0C5D6	—	0.960	P0C5D6 →
AKT1	RAC-alpha serine/threonine-protein kinase	0.959	landscape →
Q8JH47	—	0.959	Q8JH47 →